Research programme: anti-SARS-CoV-2 monoclonal antibodies - Curia/Tonix Pharmaceuticals
Latest Information Update: 30 Jan 2023
Price :
$50 *
At a glance
- Originator Curia
- Developer Tonix Pharmaceuticals Holding Corp
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research COVID 2019 infections